Grupo de Trabajo.Plan Integral de Diabetes de Andalucìa 2003-2007.Consejerìa de Salud de la Junta de Andalucìa, 2003

American Diabetes Association . Clinical Practice Recommendations.Diabetes Care January 2010 33:S1-S99

American Diabetes Association. Standards of Medical Care in Diabetes–2007.Diabetes Care 30:S4 , 2007 .

Asociación Española de Nefrología Pediátrica (AEN-PED). Sociedad Española de Diabetes (SEDIAB). Sociedad Española de Endocrinología y Nutrición (SEEN). Sociedad Española de Hipertensión Arterial, y Liga Española para la Lucha Contra la HTA (SEH-LELHA). Sociedad Española de Medicina Familiar y Comunitaria (SEMFYC). Sociedad Española de Medicina Rural y Generalista (SEMERGEN). Sociedad Española de Nefrología (SEN).Documento de consenso 2002 sobre pautas de detección, prevención y tratamiento de la NPDen España.Nefrologia .Vol. XXII. Número 6. 2002

Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease. Clin Chem 2006;52:5-18.

Levey A.S. Definition and Classification of chronic kidney disease:A position stamente from Kidney Disease : Improving Global Outcomes (KDIGO).Kidney International , Vol.67:2089-2100

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (Supl. 1): S46-S75,

Borch-Johnnsen K, Kofoed-Enevoldeen A, Deckert T, and . Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987, 294: 16521-1655

Lewis EJ, Hunsicker LG, Clarke WR et al.. Renoprotective effect of the angiotensin receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.

Parving HH, Lebinert H, Bróchner-Mortensen J et al.. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. . N Engl J Med 2001, 345: 870-878.

Mogensen C E et al. Prevención de la NPDcon especial referencia a la microalbuminuria. Lancet (ed. Esp) 1996; 28: 201-205

American Diabetes Association. Diabetic nephropathy. Diabetes Care 1997; 20 (suppl 1):  s24-s27.

Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27 (2): 167-194

Bennett P et al. Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25(1):107-112

Myers BD et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995; 47(6):1781-1789

Ruilope LM. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Journal of Hypertension 1995; 13 (suppl 2): 591-593

Mur T, Franch J, Morató J et al. Nefropatía y microalbuminuria en la diabetes tipo II. Aten Primaria 1995; 16: 516-524

Mogensen C E. Microalbuminuria: Un marcador de lesión orgánica. London. Science Press 1994

Pou Torelló JM, Mallafré Anduig JM, Ortiz de Juana MA, Toll Escobedo R, Rigla M. Fisiopatlogía y prevención de la nefropatía diabética. Avances en Diabetología 1994; 9 (suppl 1): 21-44.

Rius F, Sanmartí A. Nefropatía diabética: epidemiología, fisiopatología y tratamiento. Educación Diabetológica Profesional 1994; 4 (4): 6-18

Mata M. Microalbuminuria y diabetes. FMC 1994; 1: 104-111

Center for Disease Control. Kidney Disease. In: The Prevention and Treatment for the Prevention and Treatment of Complications of Diabetes Mellitus. Guide for Primary Care Practitioners. 1991.